Showing 4971-4980 of 6038 results for "".
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- HHS OCR: New HIPAA Guidance to Support e-Consultshttps://practicaldermatology.com/news/hhs-ocr-new-hipaa-guidance-to-support-e-consults/2460309/Practices that haven’t contracted with a telehealth platform may still be able to provide virtual consults using standard telecommunications technologies throughout the COVID-19 pandemic. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS)
- AMA: New CPT Code to Report Novel Coronavirus Testhttps://practicaldermatology.com/news/ama-new-cpt-code-to-report-novel-coronavirus-test/2460307/The Current Procedural Terminology (CPT®)Editorial Panel has approved a new addition to the CPT code set to report testing for the virus that causes COVID-19. The American Medical Association (AMA) says the code will help streamline data-driven resource and allocation planning in t
- Special Report: An Overview of Coronavirus by Dr. Jonathan Kaplanhttps://practicaldermatology.com/news/special-report-an-overview-of-coronavirus-by-dr-jonathan-kaplan/2460306/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less coll
- New from Lumenis: Meet the Stellar M22 Platformhttps://practicaldermatology.com/news/new-from-lumenis-meet-the-stellar-m22-platform/2460300/Lumenis Ltd. is launching the Stellar M22, a multi-application platform that builds on the heritage of the M22 by adding even more bells and whistles. The new Stellar M22 is now available in the USA and Europ
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- BTL Files Suit Against Allergan, Alleges Misleading Advertisinghttps://practicaldermatology.com/news/btl-files-suit-against-allergan-alleges-misleading-advertising/2460288/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Foamix’s Rosacea Candidate Shows Promise in Phase 3 Studieshttps://practicaldermatology.com/news/foamixs-rosacea-candidate-shows-promise-in-phase-3-studies-1/2460286/Foamix Pharmaceuticals Ltd.’s FMX103 1.5% Topical Minocycline Foam for rosacea performed well in an integrated efficacy analysis of two pivotal Phase 3 clinical trials presented at the 17th Annual South Beach Symposium in Dermatology in Miami,